Galena Biopharma to Present GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
May 19 2016 - 12:15PM
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company
committed to the development and commercialization of targeted
oncology therapeutics that address major unmet medical needs, today
announced that combined safety data from the Company’s GALE-401
clinical trials will be presented at the upcoming European
Hematology Association 21st Congress taking place June 9-12, 2016
in Copenhagen, Denmark. Details of the poster presentation
are as follows:
Abstract #: |
|
P675 – the abstract can be found on the
conference website here |
Title: |
|
Anagrelide Controlled Release (GALE-401) Safety
Profile Consistently Well Tolerated in Myeloproliferative Neoplasms
Patients and Healthy Volunteers |
Session Title: |
|
Myeloproliferative Neoplasms - Clinical 2
(Poster) |
Date: |
|
Saturday, June 11, 2016 |
Time: |
|
5:30 p.m. to 7:00 p.m. local time |
Location: |
|
Poster area (Hall H) |
|
|
|
About GALE-401 (Anagrelide Controlled
Release)
GALE-401 (Anagrelide Controlled Release) contains the active
ingredient anagrelide. The currently available immediate
release formulation (Agrylin® or anagrelide IR) is approved by the
FDA for the treatment of patients with thrombocythemia, secondary
to myeloproliferative disorders, to reduce the elevated platelet
count and the risk of thrombosis and to ameliorate associated
symptoms including thrombo-hemorrhagic events. Adverse events
associated with anagrelide IR, such as nausea, diarrhea, abdominal
pain, palpitations, tachycardia, and headache, may be dose and
plasma concentration dependent. Reducing the maximum plasma
concentration (Cmax) is expected to reduce side effects, but
preserve efficacy. GALE-401 is a reformulated, controlled
release version of anagrelide. A Phase 2 pilot study with
GALE-401 is ongoing.
About Myeloproliferative Neoplasms
Myeloproliferative neoplasms (MPNs) are a closely related group
of hematological malignancies in which the bone marrow cells that
produce the body's blood cells develop and function abnormally. The
main MPNs are polycythemia vera (PV), chronic myelogenous leukemia
(CML), primary myelofibrosis (PMF), and essential thrombocythemia
(ET), all of which are associated with high platelet counts.
The MPNs are progressive blood cancers that can strike anyone at
any age, and for which there is no known cure.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed
to the development and commercialization of targeted oncology
therapeutics that address major unmet medical needs. Galena’s
development portfolio is focused primarily on addressing the
rapidly growing patient populations of cancer survivors by
harnessing the power of the immune system to prevent cancer
recurrence. The Company’s pipeline consists of multiple mid- to
late-stage clinical assets, including novel cancer immunotherapy
programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax
is currently in a pivotal, Phase 3 breast cancer clinical trial
with several concurrent Phase 2 trials ongoing both as a single
agent and in combination with other therapies. GALE-301 is in a
Phase 2a clinical trial in ovarian and endometrial cancers and in a
Phase 1b given sequentially with GALE-302. For more
information, visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to,
statements about the progress of the development of Galena’s
product candidates, patient enrollment in our clinical trials, as
well as other statements related to the progress and timing of our
development activities, present or future licensing, collaborative
or financing arrangements, expected outcomes with regulatory
agencies, and projected market opportunities for product candidates
or that otherwise relate to future periods. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including those identified under “Risk Factors” in
Galena’s Annual Report on Form 10-K for the year ended December 31,
2015 and most recent Quarterly Reports on Form 10-Q filed with the
SEC. Actual results may differ materially from those contemplated
by these forward-looking statements. Galena does not undertake to
update any of these forward-looking statements to reflect a change
in its views or events or circumstances that occur after the date
of this press release.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024